Progress and prospects of quadrivalent influenza vaccine

VernacularTitle:四价流感疫苗:应用进展与展望
Author: Chenyang HUANG ¹ ; Yuqing ZHOU ; Xiaofang FU ; Xiaoxiao LIU ; Xuan LU ; Shigui YANG
Author Information

1. 浙江大学医学院附属第一医院感染性疾病诊治协同创新中心传染病诊治国家重点实验室
Keywords: Influenza vaccine; Quadrivalent influenza vaccine; Safety; Immunogenicity; Prevention
From: Chinese Journal of Clinical Infectious Diseases 2019;12(1):73-80
CountryChina
Language:Chinese
Abstract: Although the flu vaccine is the most effective strategy for preventing influenza currently,the population incidence and mortality of influenza present an unstable trend.Due to the rapid variability of influenza virus,the conventional flu vaccine components and dominant lineage are not matching;more importantly,trivalent influenza vaccine (T IV) contains only A/H3N2,A/H1N1 and B/Victoria lineage,which does not match the B/Yamagata lineage that have prevailed in recent years.Quadrivalent influenza vaccine (QIV) adds the B/Yamagata lineage,and it has been used abroad for susceptible populations.Compared with TIV,QIV provides better protection for susceptible populations and is considered to have better public health benefits.This article reviews the history of development and current status,the safety,immunogenicity,efficacy of prevention and control and cost-effectiveness of QIV,to provide reference for the promotion and implementation of influenza vaccination.